Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis.  This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]

Enzalutamide (Xtandi) Monotherapy Highly Active in Men Who Have Not Had Prior ADT

Enzalutamide (Xtandi) monotherapy induced striking declines in prostate-specific antigen (PSA) in a majority of patients with hormone-naive prostate cancer in a phase II trial, and this oral agent appears to have little effect on bone mineral density. If these findings are confirmed in a phase III trial, then enzalutamide may be an alternative to androgen [...]

FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Men with Prostate Cancer Undergoing ADT

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in men receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. Men receiving ADT are at high risk for developing fractures, including vertebral fractures, which can cause paralysis. "Bone loss [...]

What Causes Bone Fractures in Prostate Cancer?

We all know that one of the common problems many of us will confront when fighting prostate cancer is experiencing bone fractures. Somtimes these fractures happen for little or no obvious cause. Why are bone fractures, especially spontaneous fractures (without any evident reason) so common in prostate cancer? […]

Diet and Lifestyle Still Top Bone Loss Prevention Strategies

According to a new position paper from the North American Menopause Society (NAMS), despite all the new drugs that are available, diet and lifestyle should remain the first osteoporosis management tool. Only after diet and lifestyle has failed should any of the newly approved treatment options to prevent osteoporosis be considered. […]

Long-Term Effects of Intermittent Androgen Suppression on Testosterone Recovery and Bone Mineral Density: Results of a 33-Month Observational Study

A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]

Denosumab Increased Bone Mineral Density in Men With Nonmetastatic Prostate Cancer

Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]

Bone Turnover Marker Data And Additional PSA Progression Safety Analysis For Toremifene 80 Mg Phase III ADT Clinical Trial

GTx, Inc. (Nasdaq: GTXI) has conducted a number of clinical trials using toremifene citrate in both the treatment of breast and prostate cancer. Older women and men as well as women and men being treated for both breast and prostate cancers are subject to bone loss leading to an increased risk of falls and fractures. [...]

Denosumab for Bone Mineral Density (BMD)

Amgen just completed, with positive results, a three-year Phase 3 placebo-controlled trial which evaluated denosumab for the treatment of bone loss (reduction of bone mineral density –BMD) in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. One of the more common and significant side effects of ADT is loss of BMD. This loss [...]

Go to Top